在土耳其心力衰竭的流行病学
Naim Ata1, İnci Tuğçe Çöllüoğlu2, Anıl Şahin3
1General Directorate of the Health Information Systems, Ministry of Health, Ankara, Turkiye.
Turkish journal of medical sciences
|December 30, 2024
概括
在土耳其,心力衰竭 (HF) 的患病率因地区而异,黑海地区的患病率最高. 到2021年,所有地区的发病率显著下降,在所有年龄组中观察到明显的基于性别的差异.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 心力衰竭 (HF) 的流行病学数据显示,各国之间存在显著的区域差异.
- 了解这些区域差异对于有针对性的公共卫生干预和资源分配至关重要.
研究的目的:
- 调查土耳其七个地理区域心力衰竭 (HF) 的流行病情景.
- 分析包括儿科人口在内的所有年龄段的HF患病率和发病率.
主要方法:
- 利用国家电子医疗保健数据库,在2016年1月1日至2022年12月31日期间识别了首次HF诊断的患者 (ICD-10代码).
- 数据根据土耳其7个定义的地理区域系统地分类.
主要成果:
- 诊断HF的中位年龄总体为70岁,儿科病例为4岁. 黑海地区的HF患病率最高 (3.103%),东南亚纳托利亚地区的患病率最低 (1.436%).
- 在所有地区,女性患者表现出更高的HF患病率,并且比男性患者年龄更大. 从2017年到2021年,HF发病率下降,黑海地区的发病率最高,东南安纳托利亚的发病率最低.
- 儿科HF患病率为每1000人0.81,根据性别和地区有所不同. 女孩的患病率在中亚纳托利亚 (1.04/1000),而男孩的患病率在地中海地区 (0.89/1000) 较高.
结论:
- 土耳其的HF患病率与全球趋势保持一致,尽管存在区域差异.
- 在包括儿童在内的所有年龄人口统计数据中,观察到基于性别的HF患病率的显著差异.
- 截至2021年,在所有地理区域都注意到HF发病率的持续下降.
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:22Heart Failure Drugs: β-Blockers
257
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
257
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299
01:17Increased pulse rate
620
Tachycardia is a condition marked by an abnormally fast or irregular heart rate, surpassing the typical resting rate. In adults, tachycardia is characterized by a pulse rate ranging from 100 to 180 beats per minute. The increased heart rate can result in inadequate blood flow to various body parts, ultimately diminishing the oxygen supply to organs and tissues.
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
620
01:22Heart Failure Drugs: Diuretics
273
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
273
01:26Heart Failure Drugs: Inotropic Agents
395
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
395